relapsing-remitting multiple sclerosis

- Males or females
- Age >= 18 years old
- Patients after a first demyelinating event suggestive of MS (only for Betaferon) as well as patients with a definite diagnosis of RRMS (Betaferon et Rebif)
- First justified prescription of one interferon beta by subcutaneous route (as described in Summary of Product Characteristics [SmPC] of Betaferon or Rebif)
- Females of child-bearing potential must agree to practice adequate contraceptive methods over the duration of the study (not applicable for men)
- Patient can follow and comply with all study procedures of the trial protocol
- Laboratory evaluations (i.e., evaluation of hepatic enzyme gamma-GT, full blood count and differential white blood cell count [WBC]) must be available and the results must be normal.
- Written informed consent

- Any contraindication to the prescription of Betaferon or Rebif, as described in the SmPC of products:
 -- Pregnancy or lactation
 -- Known hypersensitivity to natural or recombinant interferon beta, to mannitol, to human albumin or any other excipients used
 -- History of severe depression or suicide attempt or current suicidal ideation.
 -- Patient with decompensated liver disease
 -- Epilepsy not adequately controlled by treatment
- Patient previously included in this study.
- Patient previously treated by sub-cutaneous route with either Betaferon or Rebif.
- Participation in any clinical trial within the past 30 days involving the investigational drug intake.
- Medical, psychiatric or other conditions that compromise the patient's ability to understand the patient information, to give informed consent, to comply with the trial protocol or to complete the study.